October 8, 2025

Newly Diagnosed High-Risk Multiple Myeloma: Outcomes and Management.

View Full Paper

Ask AI

Bookmark

Authors

FYFatih YaşarMarmara University EGElan Gorshein

Discussion

Member takes

Implication

This review highlights evolving therapies and induction strategies for high-risk multiple myeloma, suggesting personalized approaches may improve outcomes.

Key Points

High-risk multiple myeloma significantly affects prognosis and overall survival, with 20%-25% of patients showing adverse cytogenetic abnormalities.
Quadruplet induction regimens combining multiple drug classes show promise in improving outcomes for high-risk multiple myeloma patients.
Emerging therapies like CAR-T and bispecific antibodies are being integrated into earlier lines of treatment, possibly transforming care standards.
Personalized approaches based on cytogenetic profiling and minimal residual disease monitoring are essential for effective management of high-risk multiple myeloma.

Cite This Study

Yaşar et al. (2025) studied this question.

synapsesocial.com/papers/68e6bc5f38ca8e474d54a09f https://doi.org/10.1155/ah/6622365

View Full Paper

Ask AI

Bookmark

Implication

This review highlights evolving therapies and induction strategies for high-risk multiple myeloma, suggesting personalized approaches may improve outcomes.

Newly Diagnosed High-Risk Multiple Myeloma: Outcomes and Management.

Discussion

Member takes

Implication

Key Points

Cite This Study

Newly Diagnosed High-Risk Multiple Myeloma: Outcomes and Management.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider